Please login to the form below

Not currently logged in
Email:
Password:

Astellas files patent suit against Sandoz

Astellas Pharma has filed a lawsuit against generics manufacturer Sandoz relating to a version of Astellas' organ transplantation drug, Prograf, which Sandoz plans to market in Canada

Astellas Pharma has filed a lawsuit against Sandoz, the generic division of Novartis, relating to a version of Astellas' Prograf (tacrolimus hydrate) that Sandoz plans to market in Canada.

The suit, which was filed in the Federal Court of Canada, contains an order prohibiting marketing approval from the Canadian Minister of Health for Sandoz's generic tacrolimus hydrate before the expiration of Astellas' patent for the therapy.

Prograf is currently approved in Canada and elsewhere as an immunosuppressant following organ transplantation.

Sandoz previously launched a generic version of Prograf in the US August 2009.

14th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics